A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Status:
RECRUITING
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.